#USA #Avid Bioservices #Tustin #Dave Stewart #Transformational Leadership

Avid Bioservices Welcomes Dave Stewart

Avid Bioservices, Inc., a renowned name in the contract development and manufacturing of biological products (CDMO), has made a noteworthy announcement regarding strategic leadership changes within the organization. On November 11, 2025, the company revealed the appointment of Dave Stewart as its Chief Technology and Transformation Officer. This new position signifies a pivotal step in the company’s broader vision laid out by CEO Kenneth Bilenberg, aimed at fostering growth and embracing the next phase of evolution.

The establishment of the CTTO role reflects Avid's commitment to enhancing its service offerings and improving partnerships with clients. Bilenberg highlighted that Avid has seen remarkable growth in recent years, and the strategic investment in people, processes, and systems is critical in propelling the organization forward. Stewart's extensive experience and leading industry insights make him an ideal candidate for a role that is set to steer critical technological initiatives across the organization.

In his new capacity, Stewart will oversee the integration of Avid's transformational technology initiatives and process improvements throughout the development and manufacturing network. His focus will be on several key areas, including digital modernization, automation, and the implementation of advanced tools and services that enhance productivity and operational flexibility. Stewart expressed his enthusiasm about joining Avid, stating, “I have always admired Avid's reputation for quality and commitment to patients. Being part of a team that genuinely cares about delivering excellence is a fantastic opportunity for me.”

Stewart's leadership is expected to reinforce Avid's vision of becoming a more reliable and proactive partner for its clients at every stage of their projects. The creation of this role emphasizes Avid's commitment to continuous improvement and to maintaining agility as they expand capabilities across their manufacturing sites. In this transformation journey, the focus remains on enhancing customer experiences and ensuring that Avid continues to meet the evolving needs of the biopharmaceutical sector.

About Avid Bioservices

Avid Bioservices operates as a global CDMO specializing in the manufacture of mammalian cell cultures. Based in the United States, Avid enjoys an impeccable track record with the FDA, attracting biopharmaceutical innovators worldwide for its agility, quality, and capability to navigate complex global regulatory environments. The organization has extensive experience supporting both emerging biotech companies and large pharmaceutical corporations, providing comprehensive solutions from development through commercial supply.

Avid in Numbers

• - Over 600 batches manufactured
• - More than 275 commercial batches delivered globally
• - Six commercial products approved
• - Successfully passed 10 pre-approval/license inspections by major regulatory agencies

With Stewart's onboarding, Avid is poised for exciting opportunities that reflect its ongoing commitment to delivering high-quality products and unparalleled service.